BridgeBio Pharma, Inc. BBIO

Nasdaq; healthcare; SIC 2834, Pharmaceutical Preparations; CIK 0001743881

A

strongest fifth of 370 graded peers in healthcare

rank 42 of 370; percentile 11.1; sampling error 2.5 points; lower is stronger

A B C D E

A, the bull



Scoreboard	
Profitability	A/B percentile 18.0
Solvency	D percentile 63.4
Growth and financing	A/B percentile 21.8
Reliability	0.91 AUC filers with $591M to $2.67B assets; 95% interval 0.88 to 0.94; 160 events, 2020 to 2025
Peer failure rate	1.01% a year Item 1.03 bankruptcies, same asset band, 2012 to 2025
Size band	$591M to $2.67B assets total assets $936.0M
Standard universe	inside revenue above $1M and assets above $10M
Warnings	none triggered not computable: distress
Inputs computable	7 of 14
Graded from	filings received through Feb 24, 2026 242 days before the rescan; latest periodic filing 10-Q received Aug 10, 2026
Last close	$68.52 2026-10-23; market equity $13.4B; no price enters the letter

Share price, twelve months to the rescan



Split-adjusted close. Each lollipop is a rescan and carries the letter held then.

Letter at every rescan, 2012 to 2026



Sector percentile at each rescan, stronger toward the top; facts filed by each date only.

Business, in the company's words

opening of Item 1 of the 10-K received Feb 24, 2026

BridgeBio Pharma, Inc. is a commercial-stage, multi-product biopharmaceutical company organized around a portfolio operating model to discover, develop, and deliver medicines for patients with genetic diseases. We seek to translate advances in genetic science into therapies for patient populations with significant unmet medical needs. Since our founding 10 years ago, we have advanced multiple programs from discovery through regulatory approval and commercialization. To date, more than 8,500 patients have been treated with our approved medicines, and we have obtained U.S. Food and Drug Administration (the "FDA") approval for three products.

The fourteen inputs

lower percentile is stronger; sleeves and inputs within a sleeve carry equal weight

Input	Value	Peer median	Percentile, 0 to 100	Pct	Peers	Period end
Profitability, sleeve percentile 18.0						
Gross profitability	51.4%	32.3%		22.3	368	2025-12-31
Return on invested capital	not computable	9.3%				

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

prior invested-capital observation is 2192 days earlier						
Accruals ratio	(30.9%)	(6.6%)		13.7	809	2025-12-31
Gross margin stability, five years	not computable	2.8 pts				
five annual gross margins are required; found 4						
Solvency, sleeve percentile 63.4						
Twelve-month failure probability	not computable	0.07%				
latest liabilities, cash plus short-term investments, book equity, and shares are required						
Altman Z double-prime	(14.22)	(0.33)		68.7	754	2025-12-31
Net debt to EBITDA	not computable	1.82x				
EBITDA must exceed $100,000						
Interest coverage	not computable	(4.51x)				
latest aligned inputs end 2023-12-31; latest annual assets end 2025-12-31						
Current ratio	2.77x	2.94x		58.2	836	2025-12-31
Growth and financing, sleeve percentile 21.8						
Revenue growth, three-year compound	86.3%	10.1%		6.8	413	2025-12-31
Free cash flow growth, three-year compound	not computable	10.9%				
current FCF must be positive and base FCF must exceed $100,000						
Reinvestment rate	not computable	37.1%				
pretax income must exceed the validity floor and imply a 0%-100% tax rate						
Asset growth, three years	14.5%	2.1%		26.8	702	2025-12-31
Net share issuance, one year	1.9%	2.5%		31.9	634	2026-02-12

Among 370 peers

healthcare; letters are fifths of this list



Composite score of every graded peer, smoothed; vertical rules are the letter band edges; stronger to the left.

Rank	Company	Percentile	Letter	Warnings
37	LivaNova plc (LIVN)	9.8	A	fortress balance sheet
38	TG Therapeutics, Inc. (TGTX)	10.0	A	
39	Viridian Therapeutics, Inc.\DE (VRDN)	10.3	A	dilution, fortress balance sheet
40	TransMedics Group, Inc. (TMDX)	10.6	A	
41	Niagen Bioscience, Inc. (NAGE)	10.8	A	
42	BridgeBio Pharma, Inc. (BBIO)	11.1	A	
43	Orthopediatrics Corp. (KIDS)	11.4	A	
44	PRO DEX Inc. (PDEX)	11.7	A	
45	Sanara MedTech Inc. (SMTI)	11.9	A	
46	Idexx Laboratories Inc. (IDXX)	12.2	A	
47	Natera, Inc. (NTRA)	12.5	A	fortress balance sheet

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

What the price implies

at the 2026-10-23 close; none of these enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	47.5%	7.7%	75
Distance from 52-week high	(24.0%)	(31.4%)	59
EBIT to enterprise value	(3.4%)	(1.5%)	45
Free cash flow yield	(3.3%)	(1.0%)	45
Book value to price	(0.19)	0.28	6
Sales to price	0.04	0.30	12
Composite equity issuance, five years	27.2%	20.5%	54
Relative strength against the sector, log excess return	0.18	(0.14)	75

Diagnostics

shown on every report; none enters the grade

Measure	Value
Piotroski F-score 3 of 9, period end 2025-12-31	
Return on assets above zero	fail
Operating cash flow above zero	fail
Return on assets improved	pass
Operating cash flow exceeds net income	pass
Long-term leverage fell	fail
Current ratio improved	fail
No new shares issued	fail
Gross margin improved	fail
Asset turnover improved	pass
Cash, filings, liquidity	
Cash and equivalents	$677.9M
Operating cash flow, four quarters	-$434.4M
Months of runway	18.7
Days since last periodic filing	75 (10-Q received Aug 10, 2026)
Median daily dollar volume, 63 sessions	$175.4M

Sources

every fact behind the inputs; each row links to its filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$502.1M	2025-12-31	2026-02-24	10-K	26-000009
2	cost of revenue	us-gaap:CostOfRevenue	$21.0M	2025-12-31	2026-02-24	10-K	26-000009
3	assets	us-gaap:Assets	$936.0M	2025-12-31	2026-02-24	10-K	26-000009
4	operating income	us-gaap:OperatingIncomeLoss	-$523.4M	2025-12-31	2026-02-24	10-K	26-000009
5	pretax income	us-gaap:IncomeLossFromContinuingOperationsBeforeInc...	-$732.5M	2025-12-31	2026-02-24	10-K	26-000009
6	income tax	us-gaap:IncomeTaxExpenseBenefit	$435,000	2025-12-31	2026-02-24	10-K	26-000009
7	total debt	us-gaap:LongTermDebt	$2.0B	2025-12-31	2026-02-24	10-K	26-000009
8	book equity	us-gaap:StockholdersEquity	-$2.1B	2025-12-31	2026-02-24	10-K	26-000009
9	cash	us-gaap:CashAndCashEquivalentsAtCarryingValue	$570.1M	2025-12-31	2026-02-24	10-K	26-000009
10	total debt	us-gaap:LongTermDebt	$95.4M	2019-12-31	2020-03-03	10-K	20-008260
11	book equity	us-gaap:StockholdersEquity	$408.5M	2019-12-31	2021-02-25	10-K	21-008969
12	cash	us-gaap:CashAndCashEquivalentsAtCarryingValue	$363.8M	2019-12-31	2022-02-25	10-K	22-002030
13	net income	us-gaap:ProfitLoss	-$732.9M	2025-12-31	2026-02-24	10-K	26-000009
14	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$445.9M	2025-12-31	2026-02-24	10-K	26-000009
15	assets	us-gaap:Assets	$919.3M	2024-12-31	2026-02-24	10-K	26-000009
16	current assets	us-gaap:AssetsCurrent	$797.7M	2025-12-31	2026-02-24	10-K	26-000009
17	current liabilities	us-gaap:LiabilitiesCurrent	$288.0M	2025-12-31	2026-02-24	10-K	26-000009
18	retained earnings	us-gaap:RetainedEarningsAccumulatedDeficit	-$3.8B	2025-12-31	2026-02-24	10-K	26-000009

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

19	liabilities	us-gaap:Liabilities	$3.0B	2025-12-31	2026-02-24	10-K	26-000009
20	depreciation amortization	us-gaap:DepreciationDepletionAndAmortization	$5.4M	2025-12-31	2026-02-24	10-K	26-000009
21	operating income	us-gaap:OperatingIncomeLoss	-$607.4M	2023-12-31	2026-02-24	10-K	26-000009
22	interest expense	us-gaap:InterestExpense	$81.3M	2023-12-31	2024-02-22	10-K	24-018811
23	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$221.9M	2024-12-31	2026-02-24	10-K	26-000009
24	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$9.3M	2023-12-31	2026-02-24	10-K	26-000009
25	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$77.6M	2022-12-31	2025-02-20	10-K	25-024119
26	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$1.1M	2025-12-31	2026-02-24	10-K	26-000009
27	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$520.7M	2024-12-31	2026-02-24	10-K	26-000009
28	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$933,000	2024-12-31	2026-02-24	10-K	26-000009
29	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$527.7M	2023-12-31	2026-02-24	10-K	26-000009
30	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$1.3M	2023-12-31	2026-02-24	10-K	26-000009
31	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-$419.5M	2022-12-31	2025-02-20	10-K	25-024119
32	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	$4.8M	2022-12-31	2025-02-20	10-K	25-024119
33	current assets	us-gaap:AssetsCurrent	$720.7M	2024-12-31	2026-02-24	10-K	26-000009
34	current liabilities	us-gaap:LiabilitiesCurrent	$154.4M	2024-12-31	2026-02-24	10-K	26-000009
35	assets	us-gaap:Assets	$546.4M	2023-12-31	2025-02-20	10-K	25-024119
36	assets	us-gaap:Assets	$623.0M	2022-12-31	2024-02-22	10-K	24-018811
37	shares outstanding	dei:EntityCommonStockSharesOutstanding	193,862,871	2026-02-12	2026-02-24	10-K	26-000009
38	shares outstanding	dei:EntityCommonStockSharesOutstanding	190,188,626	2025-02-13	2025-02-20	10-K	25-024119

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.